Inhalable ciprofloxacin/polymyxin B dry powders in respiratory infection therapy

The current study focused on the formulation, physicochemical characterization, and antibacterial susceptibility testing of inhalable spray dried powders containing ciprofloxacin (CIP) and polymyxin B sulfate (PMB). CIP nanosuspensions with an average particle diameter of 435.9 ± 9.3 nm were initial...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhengqi Xu, Hriday Bera, Hengzhuang Wang, Junwei Wang, Dongmei Cun, Yu Feng, Mingshi Yang
Format: Article
Language:English
Published: Compuscript Ltd 2023-03-01
Series:Acta Materia Medica
Online Access:https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2022-0050
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850121952629358592
author Zhengqi Xu
Hriday Bera
Hengzhuang Wang
Junwei Wang
Dongmei Cun
Yu Feng
Mingshi Yang
author_facet Zhengqi Xu
Hriday Bera
Hengzhuang Wang
Junwei Wang
Dongmei Cun
Yu Feng
Mingshi Yang
author_sort Zhengqi Xu
collection DOAJ
description The current study focused on the formulation, physicochemical characterization, and antibacterial susceptibility testing of inhalable spray dried powders containing ciprofloxacin (CIP) and polymyxin B sulfate (PMB). CIP nanosuspensions with an average particle diameter of 435.9 ± 9.3 nm were initially obtained using the wet-milling protocol and subsequently co-spray dried with PMB solutions to yield inhalable dry powders. The Powder X-Ray Diffraction (P-XRD) results showed that the wet-milled CIP nanoparticles were in a 4.8 hydrate state, which were transformed to 3.7 hydrates and amorphous materials after co-spray drying. The PMB remained in an amorphous state in the dry powders. Differential Scanning Calorimetry (DSC) analyses revealed that the glass transition temperatures (T g s) of the co–spray dried formulations were higher than the T g of CIP, but lower than the T g of PMB. Fourier Transform Infrared Spectrometer (FTIR) studies suggested the existence of π - π interactions between CIP and PMB in the co-spray dried powders. These powders also retained antimicrobial effects against Pseudomonas aeruginosa strain PAO1. In addition, the spray-dried powder formulations exhibited satisfactory solid-state stability and aerodynamic characteristics when stored under 3% relative humidity and 20 ± 5 °C for 4 months. Overall, the newly developed inhalable CIP/PMB dry powders are a promising therapeutic strategy for respiratory tract infections.
format Article
id doaj-art-2a80f44489d944d680721d9f8b68baed
institution OA Journals
issn 2737-7946
language English
publishDate 2023-03-01
publisher Compuscript Ltd
record_format Article
series Acta Materia Medica
spelling doaj-art-2a80f44489d944d680721d9f8b68baed2025-08-20T02:34:56ZengCompuscript LtdActa Materia Medica2737-79462023-03-012214215610.15212/AMM-2022-0050Inhalable ciprofloxacin/polymyxin B dry powders in respiratory infection therapyZhengqi XuHriday BeraHengzhuang WangJunwei WangDongmei CunYu FengMingshi YangThe current study focused on the formulation, physicochemical characterization, and antibacterial susceptibility testing of inhalable spray dried powders containing ciprofloxacin (CIP) and polymyxin B sulfate (PMB). CIP nanosuspensions with an average particle diameter of 435.9 ± 9.3 nm were initially obtained using the wet-milling protocol and subsequently co-spray dried with PMB solutions to yield inhalable dry powders. The Powder X-Ray Diffraction (P-XRD) results showed that the wet-milled CIP nanoparticles were in a 4.8 hydrate state, which were transformed to 3.7 hydrates and amorphous materials after co-spray drying. The PMB remained in an amorphous state in the dry powders. Differential Scanning Calorimetry (DSC) analyses revealed that the glass transition temperatures (T g s) of the co–spray dried formulations were higher than the T g of CIP, but lower than the T g of PMB. Fourier Transform Infrared Spectrometer (FTIR) studies suggested the existence of π - π interactions between CIP and PMB in the co-spray dried powders. These powders also retained antimicrobial effects against Pseudomonas aeruginosa strain PAO1. In addition, the spray-dried powder formulations exhibited satisfactory solid-state stability and aerodynamic characteristics when stored under 3% relative humidity and 20 ± 5 °C for 4 months. Overall, the newly developed inhalable CIP/PMB dry powders are a promising therapeutic strategy for respiratory tract infections.https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2022-0050
spellingShingle Zhengqi Xu
Hriday Bera
Hengzhuang Wang
Junwei Wang
Dongmei Cun
Yu Feng
Mingshi Yang
Inhalable ciprofloxacin/polymyxin B dry powders in respiratory infection therapy
Acta Materia Medica
title Inhalable ciprofloxacin/polymyxin B dry powders in respiratory infection therapy
title_full Inhalable ciprofloxacin/polymyxin B dry powders in respiratory infection therapy
title_fullStr Inhalable ciprofloxacin/polymyxin B dry powders in respiratory infection therapy
title_full_unstemmed Inhalable ciprofloxacin/polymyxin B dry powders in respiratory infection therapy
title_short Inhalable ciprofloxacin/polymyxin B dry powders in respiratory infection therapy
title_sort inhalable ciprofloxacin polymyxin b dry powders in respiratory infection therapy
url https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2022-0050
work_keys_str_mv AT zhengqixu inhalableciprofloxacinpolymyxinbdrypowdersinrespiratoryinfectiontherapy
AT hridaybera inhalableciprofloxacinpolymyxinbdrypowdersinrespiratoryinfectiontherapy
AT hengzhuangwang inhalableciprofloxacinpolymyxinbdrypowdersinrespiratoryinfectiontherapy
AT junweiwang inhalableciprofloxacinpolymyxinbdrypowdersinrespiratoryinfectiontherapy
AT dongmeicun inhalableciprofloxacinpolymyxinbdrypowdersinrespiratoryinfectiontherapy
AT yufeng inhalableciprofloxacinpolymyxinbdrypowdersinrespiratoryinfectiontherapy
AT mingshiyang inhalableciprofloxacinpolymyxinbdrypowdersinrespiratoryinfectiontherapy